Helene Esperou

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Five-year immunogenicity and safety follow-up of the PREVAC randomized Trial of Vaccines for Zaire Ebola Virus Disease.

Five-year immunogenicity and safety follow-up of the PREVAC randomized Trial of Vaccines for Zaire Ebola Virus Disease.

Journal: medRxiv : the preprint server for health sciences

Published: June 22, 2026

Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial.

Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: July 23, 2025

Revisiting the link between COVID-19 incidence and infection fatality rate during the first pandemic wave.

Revisiting the link between COVID-19 incidence and infection fatality rate during the first pandemic wave.

Journal: Scientific reports

Published: October 21, 2024

sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial.

sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial.

Journal: Scientific reports

Published: August 27, 2024

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.

Journal: The Journal of infection

Published: February 02, 2024

Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.

Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: September 28, 2023

Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study.

Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study.

Journal: Contemporary clinical trials

Published: February 03, 2023

Randomized Trial of Vaccines for Zaire Ebola Virus Disease.

Randomized Trial of Vaccines for Zaire Ebola Virus Disease.

Journal: The New England journal of medicine

Published: December 14, 2022

Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.

Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.

Journal: Pharmacology research & perspectives

Published: November 29, 2022

Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia.

Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia.

Journal: British journal of clinical pharmacology

Published: October 14, 2022

Title Not Found

Title Not Found

Journal: Therapie

Published: October 13, 2022

Platform trials.

Platform trials.

Journal: Therapie

Published: October 13, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026